Literature DB >> 12356718

The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus.

Elisa Scarselli1, Helenia Ansuini, Raffaele Cerino, Rosa Maria Roccasecca, Stefano Acali, Gessica Filocamo, Cinzia Traboni, Alfredo Nicosia, Riccardo Cortese, Alessandra Vitelli.   

Abstract

We discovered that the hepatitis C virus (HCV) envelope glycoprotein E2 binds to human hepatoma cell lines independently of the previously proposed HCV receptor CD81. Comparative binding studies using recombinant E2 from the most prevalent 1a and 1b genotypes revealed that E2 recognition by hepatoma cells is independent from the viral isolate, while E2-CD81 interaction is isolate specific. Binding of soluble E2 to human hepatoma cells was impaired by deletion of the hypervariable region 1 (HVR1), but the wild-type phenotype was recovered by introducing a compensatory mutation reported previously to rescue infectivity of an HVR1-deleted HCV infectious clone. We have identified the receptor responsible for E2 binding to human hepatic cells as the human scavenger receptor class B type I (SR-BI). E2-SR-BI interaction is very selective since neither mouse SR-BI nor the closely related human scavenger receptor CD36, were able to bind E2. Finally, E2 recognition by SR-BI was competed out in an isolate-specific manner both on the hepatoma cell line and on the human SR-BI-transfected cell line by an anti-HVR1 monoclonal antibody.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12356718      PMCID: PMC129051          DOI: 10.1093/emboj/cdf529

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  50 in total

Review 1.  CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism.

Authors:  M Febbraio; D P Hajjar; R L Silverstein
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

2.  Hypervariable regions in the putative glycoprotein of hepatitis C virus.

Authors:  M Hijikata; N Kato; Y Ootsuyama; M Nakagawa; S Ohkoshi; K Shimotohno
Journal:  Biochem Biophys Res Commun       Date:  1991-02-28       Impact factor: 3.575

3.  Murine SR-BI, a high density lipoprotein receptor that mediates selective lipid uptake, is N-glycosylated and fatty acylated and colocalizes with plasma membrane caveolae.

Authors:  J Babitt; B Trigatti; A Rigotti; E J Smart; R G Anderson; S Xu; M Krieger
Journal:  J Biol Chem       Date:  1997-05-16       Impact factor: 5.157

4.  Monoclonal antibodies with broad specificity for hepatitis C virus hypervariable region 1 variants can recognize viral particles.

Authors:  A Cerino; A Meola; L Segagni; M Furione; S Marciano; M Triyatni; T J Liang; A Nicosia; M U Mondelli
Journal:  J Immunol       Date:  2001-10-01       Impact factor: 5.422

Review 5.  Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain?

Authors:  M U Mondelli; A Cerino; L Segagni; A Meola; A Cividini; E Silini; A Nicosia
Journal:  Antiviral Res       Date:  2001-11       Impact factor: 5.970

6.  Neutralization of pseudotyped vesicular stomatitis virus expressing hepatitis C virus envelope glycoprotein 1 or 2 by serum from patients.

Authors:  L Martin Lagging; Keith Meyer; Johan Westin; Rune Wejstål; Gunnar Norkrans; Magnus Lindh; Ranjit Ray
Journal:  J Infect Dis       Date:  2002-04-01       Impact factor: 5.226

7.  Caveolar endocytosis of simian virus 40 is followed by brefeldin A-sensitive transport to the endoplasmic reticulum, where the virus disassembles.

Authors:  Leonard C Norkin; Howard A Anderson; Scott A Wolfrom; Ariella Oppenheim
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

8.  Association of the caveola vesicular system with cellular entry by filoviruses.

Authors:  Cyril J Empig; Mark A Goldsmith
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

9.  Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles.

Authors:  Reginald F Clayton; Ania Owsianka; Jim Aitken; Susan Graham; David Bhella; Arvind H Patel
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

10.  Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding.

Authors:  Miriam Triyatni; John Vergalla; Anthony R Davis; Kenneth G Hadlock; Steven K H Foung; T Jake Liang
Journal:  Virology       Date:  2002-06-20       Impact factor: 3.616

View more
  487 in total

1.  Impact of intra- and interspecies variation of occludin on its function as coreceptor for authentic hepatitis C virus particles.

Authors:  Sandra Ciesek; Sandra Westhaus; Melanie Wicht; Ilka Wappler; Sylvana Henschen; Christoph Sarrazin; Nabila Hamdi; Ahmed I Abdelaziz; Christian P Strassburg; Heiner Wedemeyer; Michael P Manns; Thomas Pietschmann; Thomas von Hahn
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature.

Authors:  Michelle C Sabo; Vincent C Luca; Stuart C Ray; Jens Bukh; Daved H Fremont; Michael S Diamond
Journal:  Virology       Date:  2011-11-12       Impact factor: 3.616

3.  Reproduction in vitro of a quasispecies from a hepatitis C virus-infected patient and determination of factors that influence selection of a dominant species.

Authors:  Kazunori Kawaguchi; Kristina Faulk; Robert H Purcell; Suzanne U Emerson
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

4.  EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.

Authors:  Joachim Lupberger; Mirjam B Zeisel; Fei Xiao; Christine Thumann; Isabel Fofana; Laetitia Zona; Christopher Davis; Christopher J Mee; Marine Turek; Sebastian Gorke; Cathy Royer; Benoit Fischer; Muhammad N Zahid; Dimitri Lavillette; Judith Fresquet; François-Loïc Cosset; S Michael Rothenberg; Thomas Pietschmann; Arvind H Patel; Patrick Pessaux; Michel Doffoël; Wolfgang Raffelsberger; Olivier Poch; Jane A McKeating; Laurent Brino; Thomas F Baumert
Journal:  Nat Med       Date:  2011-04-24       Impact factor: 53.440

5.  Direct binding of the ligand PSG17 to CD9 requires a CD9 site essential for sperm-egg fusion.

Authors:  Diego A Ellerman; Cam Ha; Paul Primakoff; Diana G Myles; Gabriela S Dveksler
Journal:  Mol Biol Cell       Date:  2003-10-03       Impact factor: 4.138

6.  Significance of pretreatment analysis of hepatitis C virus genotype 1b hypervariable region 1 sequences to predict antiviral outcome.

Authors:  Catherine Gaudy; Alain Moreau; Pascal Veillon; Stephanie Temoin; Francoise Lunel; Alain Goudeau
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

7.  A human claudin-1-derived peptide inhibits hepatitis C virus entry.

Authors:  Youhui Si; Shufeng Liu; Xiuying Liu; Jana L Jacobs; Min Cheng; Yuqiang Niu; Qi Jin; Tianyi Wang; Wei Yang
Journal:  Hepatology       Date:  2012-06-11       Impact factor: 17.425

Review 8.  Viral hepatitis: new data on hepatitis C infection.

Authors:  Erzsébet Szabó; Gábor Lotz; Csilla Páska; András Kiss; Zsuzsa Schaff
Journal:  Pathol Oncol Res       Date:  2003-12-22       Impact factor: 3.201

9.  CD81-dependent binding of hepatitis C virus E1E2 heterodimers.

Authors:  Laurence Cocquerel; Chiung-Chi Kuo; Jean Dubuisson; Shoshana Levy
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Transient activation of the PI3K-AKT pathway by hepatitis C virus to enhance viral entry.

Authors:  Zhe Liu; Yongjun Tian; Keigo Machida; Michael M C Lai; Guangxiang Luo; Steven K H Foung; Jing-hsiung James Ou
Journal:  J Biol Chem       Date:  2012-10-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.